ADMA Biologics's 15min chart: RSI Overbought, KDJ Death Cross signal.

ADMA Biologics's 15-minute chart has triggered an overbought RSI signal and a KDJ death cross at 09/23/2025 09:45, indicating that the stock price has risen too rapidly and exceeds its fundamental support. This momentum shift towards the downside suggests a potential further decrease in stock price.

On September 23, 2025, ADMA Biologics Inc. (NASDAQ: ADMA) triggered an overbought RSI signal and a KDJ death cross, indicating a potential shift in the stock's momentum towards the downside. This technical analysis suggests that the stock price may experience a further decrease following its rapid ascent. The RSI (Relative Strength Index) reading of 70 and the KDJ (Keltner Channels) death cross signal a warning of overvaluation and potential reversal in the stock's price trend.

ADMA Biologics Inc. is a biopharmaceutical company with a market capitalization of $3.797 billion as of September 19, 2025. The company reported a 14% year-over-year increase in total revenue for the second quarter of 2025, reaching $122 million. Despite its strong financial performance, the stock has seen significant volatility, with a one-month return of -6.47% and a 20.57% decrease in value over the last 52 weeks.

Renaissance Investment Management's Small Cap Growth Strategy highlighted ADMA Biologics Inc. in its Q2 2025 investor letter, noting that while the company has potential, certain AI stocks offer greater upside potential and carry less downside risk. As of the end of the second quarter, 33 hedge fund portfolios held ADMA Biologics Inc., indicating some investor interest but not a widespread presence among the most popular stocks among hedge funds.

Investors should closely monitor ADMA Biologics Inc.'s stock price and technical indicators to make informed decisions. The recent signals suggest a potential decrease in the stock's value, but further analysis and market conditions will determine the extent of the downtrend.